Core Insights - Idorsia Ltd reports strong financial results for the first nine months of 2025, driven by significant sales growth of QUVIVIQ and reduced operating expenses, positioning the company towards profitability by the end of 2027 [2][3][6] Financial Performance - Net revenue for the first nine months of 2025 reached CHF 173 million, a substantial increase from CHF 53 million in the same period of 2024, primarily due to product sales of CHF 92 million and contract revenues of CHF 78 million [10][13] - Operating expenses decreased to CHF 162 million in 2025 from CHF 211 million in 2024, reflecting a disciplined approach to cost management [14] - The company reported an operating income of CHF 23 million for the first nine months of 2025, compared to an operating loss of CHF 154 million in the same period of 2024 [10] Product Performance - QUVIVIQ's global net sales increased by over 130% year-on-year to CHF 91 million in the first nine months of 2025, with sales in Europe reaching CHF 73 million [6][7] - The company maintains its sales guidance for QUVIVIQ at around CHF 130 million for 2025, indicating confidence in continued market performance [7][23] Research and Development - Idorsia is advancing its pipeline, including the pediatric study of daridorexant and ongoing discussions for the commercialization of TRYVIO, a new hypertension therapy [11][19] - The company is also progressing with three first-in-class chemokine receptor antagonists and a synthetic glycan vaccine platform, indicating a robust R&D strategy [11] Liquidity and Financing - As of September 30, 2025, Idorsia's liquidity stood at CHF 64 million, with additional financing of CHF 65.6 million extending its cash runway into 2028 [22] - The company has successfully completed a financing round with strong demand from institutional investors, enhancing its financial stability [6][14]
QUVIVIQ sales up >130% driving Idorsia toward profitability - 9M 2025 results
The Manila Times·2025-10-30 06:16